# The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

> **NCT00857259** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 16 (actual)

## Conditions studied

- Choroidal Neo-Vascular Age-onset Macular Degeneration
- Age-related Macular Degeneration

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00857259
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2011-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00857259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00857259, "The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00857259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*